Literature DB >> 8478710

In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy.

K Higashi1, A C Clavo, R L Wahl.   

Abstract

The tumor cell uptake of three tracers that can be labeled with isotopes suitable for PET imaging--FDG, L-methionine and thymidine--were examined in vitro in a human ovarian carcinoma cell line (HTB77IP3) at varying times following 30 Gy 60Co irradiation and were compared to a nonirradiated control group. FDG, methionine and thymidine uptake per tissue culture well all increased following irradiation when compared to basal values, although to a much lower extent than the increases in uptake seen in a nonirradiated group. This increase in tracer uptake occurred despite a 6.25-fold decline in viable cell numbers. When examined per cell, FDG uptake per cell increased 9.77-fold, methionine 7.82-fold and thymidine 9.48-fold over basal levels from Day 0 to Day 12 following irradiation. Part of these increases may be due to giant cell formation and/or radiation repair processes that require energy, protein and DNA substrates. While the in vitro system differs from in vivo systems due to the absence of a blood supply in vitro, a lack of infiltrating leukocytes and other factors, our data suggest that early assessment of human adenocarcinoma response to radiotherapy by PET with these tracers may be complicated by this normal increase in tracer uptake postirradiation. Clearly, in this human cancer cell line, early radiation-induced cell death is not associated with an early decline in tumor cell uptake of FDG, methionine or thymidine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478710

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

Review 1.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study.

Authors:  Fatma Al-Saeedi
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

Review 3.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

Review 4.  [18F-FDG-PET in therapy response of esophageal cancer].

Authors:  H A Wieder; K Herrmann; K Ott; B J Krause
Journal:  Radiologe       Date:  2007-02       Impact factor: 0.635

5.  Update of PET and PET/CT for hepatobiliary and pancreatic malignancies.

Authors:  Dominique Delbeke; William H Martin
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

6.  Assessment of therapy response in malignant tumours with 18F-fluorothymidine.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09       Impact factor: 9.236

Review 7.  Monitoring chemotherapy and radiotherapy of solid tumors.

Authors:  Wolfgang A Weber; Hinrich Wieder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

8.  Carbon-11-methionine positron emission tomography imaging of chordoma.

Authors:  Hong Zhang; Kyosan Yoshikawa; Katsumi Tamura; Kenji Sagou; Mei Tian; Tetsuya Suhara; Susumu Kandatsu; Kazutoshi Suzuki; Shuji Tanada; Hirohiko Tsujii
Journal:  Skeletal Radiol       Date:  2004-07-28       Impact factor: 2.199

9.  Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer.

Authors:  Julia Tchou; Seema S Sonnad; Meredith R Bergey; Sandip Basu; John Tomaszewski; Abass Alavi; Mitchell Schnall
Journal:  Mol Imaging Biol       Date:  2009-12-12       Impact factor: 3.488

Review 10.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.